Targeting a specific metabolic pathway to improve cognitive function in cancer survivors
PQ#12; Targeting Nampt-mediated NAD+ metabolism in chemobrain
['FUNDING_R01'] · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · NIH-10759020
This study is looking into how chemotherapy can affect memory and thinking in cancer survivors, and it’s testing if a supplement called NMN can help improve brain function after treatment.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RUTGERS BIOMEDICAL AND HEALTH SCIENCES (nih funded) |
| Locations | 1 site (Newark, UNITED STATES) |
| Trial ID | NIH-10759020 on ClinicalTrials.gov |
What this research studies
This research investigates the cognitive dysfunction known as chemobrain, which affects cancer survivors after chemotherapy. The study focuses on understanding the molecular mechanisms behind this condition, particularly the role of the Nampt-mediated NAD+ metabolic pathway. By using the chemotherapy drug cisplatin, researchers aim to explore how it impacts brain function and memory. They are also testing whether increasing NAD+ levels with a precursor called nicotinamide mononucleotide (NMN) can reverse cognitive deficits caused by chemotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer survivors who have experienced cognitive impairments following chemotherapy.
Not a fit: Patients who have not undergone chemotherapy or do not experience cognitive dysfunction related to cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments that improve cognitive function in cancer survivors suffering from chemobrain.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways for cognitive improvement, suggesting potential success for this approach.
Where this research is happening
Newark, UNITED STATES
- RUTGERS BIOMEDICAL AND HEALTH SCIENCES — Newark, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JANG, MI-HYEON — RUTGERS BIOMEDICAL AND HEALTH SCIENCES
- Study coordinator: JANG, MI-HYEON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Neoplastic Disease Chemotherapeutic Agents, anti-cancer drug, anticancer agent